News

Roxane is a well-established US specialty generics company with a highly differentiated product portfolio and best-in-class R&D capabilities. Under the terms of the acquisition, on closing of the

ZS-9 is an insoluble, non-absorbed zirconium silicate with a three-dimensional crystalline lattice structure that was designed to preferentially trap potassium ions. The potassium selectivity of ZS-9 allows high

The breakthrough status was based on the results from a Phase II clinical trial (Study 205) of lenvatinib in advanced or metastatic renal cell carcinoma following one prior

The multicenter, open-label treatment-optimized, double-blind, randomized, placebo-controlled, forced-withdrawal, parallel group Phase III trial is expected to generate top-line data by year-end. HLD200 is a new delayed and extended

In the NDA, OPKO seeks approval of Rayaldee for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD)

Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95 million in cash. In

As part of the agreement, the two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase 1 testing and plan to initiate

The company noted that anti-RSPO3 is the first drug in its class to target the R-spondin-LGR pathway, an important cancer stem cell pathway identified by OncoMed researchers. In

Currently, Azedra is being evaluated in a pivotal Phase IIb trial, which is being conducted under a Special Protocol Assessment Agreement (SPA), and has received orphan drug and